pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Yartemlea
drug
save

narsoplimab

Marketedupdated 3mo ago
by $OMER OMEROS CORP
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval4 co-mentions · 1 sources
  • drugYARTEMLEA4 co-mentions · 1 sources
  • company$OMEROMEROS CORP2 co-mentions · 1 sources

all catalysts(1)

approval · 1
Dec 23, 2025
approval
$OMER13.62+2.79%
8mo ago
YARTEMLEA (NARSOPLIMAB-WUUG) — FDA approval
narsoplimab
→

Trials studying narsoplimab

  • phase2Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721terminatedn=31
  • —Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimabapproved for marketing
  • phase3Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrometerminatedn=6
  • phase2Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMArecruitingn=18

News(0)

no news has mentioned this drug yet

brand
Yartemlea
generic
narsoplimab-wuug
MOA
12.1 Mechanism of Action Narsoplimab-wuug inhibits MASP-2, the effector enzyme of the lectin pathway of the complement system, blocking lectin-dependent activation of complement component 3 (C3) and C4 without affecting the classical and alternative pathways of complement. In hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), MASP-2 inhibition is thought to prevent lectin pathway-mediated cellular injury, including endothelial cell injury in small blood vessels.
indication
Coronavirus Disease 2019 (COVID-19)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 32m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?